LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Lorlatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 01 May 2024 Planned End Date changed from 12 Jun 2027 to 28 Dec 2026.
- 01 May 2024 Planned primary completion date changed from 12 Jun 2027 to 28 Dec 2026.
- 29 Mar 2024 Planned End Date changed from 28 Dec 2026 to 12 Jun 2027.